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INTRODUCTION
In patients with multiple medical comorbidities which preclude
surgical therapy for early stage endometrioid typ e endometrial cancer,
radiotherapy is considered to be the only curative treatment.1 With the
advent of iridium-192 high dose rate (HDR) brachytherapy, as well as
more sophisticated three dimensional computed tomography (CT) and
magnetic resonance imaging (MRI), HDR intracavitary brachytherapy
dosimetry has become much more precise, allowing higher doses to be
used for target tissues, with lower doses reaching surrounding structures,
such as bladder and bowel.2

AIM
To report the experience with high dose rate, image guided intracavitary
brachytherapy in the treatment of medically inoperable, early stage
endometrial cancer.

METHODS
All American Joint Committee on Cancer (AJCC) stage T1a or T1b
endometrioid type endometrial cancer, with medical comorbidities precluding
surgical management treated at Temple University Hospital since 2010 were
reviewed. Exclusion criteria were any evidence of nodal or cervical disease, or
histologic types other than endometrioid.
All treatment planning utilized CT imaging following placement of HDR
applicators (tandem with ring or tandem with ovoids). Prior to 2016, a high-risk
clinical target volume was defined by the radiation oncologist as approximately
2 cm myometrial depth. In 2016, a protocol was initiated where gross tumor
volume (GTV) was defined as the width of the endometrial stripe as
demonstrated by MRI. Clinical target volume (CTV) was defined as the entire
uterine corpus, cervix, and proximal 4-5 cm of vaginal wall, excluding fibroids.
Goal cumulative dose to 90 percent of the tissue volume (D90) in equivalent 2
Gy fractions (EDQ2, α/ß=10) was 80-90 Gy for GTV and 60 Gy for CTV.
The decision to give external beam radiotherapy (EBRT) prior to
brachytherapy was made on the basis of MRI-demonstrated myometrial
invasion, indicating increased risk of occult pelvic nodal disease, or when it was
thought that intracavitary brachytherapy alone would not deliver a sufficient
dose to the entire CTV, most often in the setting of fibroids.
To estimate the delivered doses given to the GTV and CTV in the patients who
were dosed by the older protocol, isodose distributions were mapped onto the
original treatment plans. GTV and CTV doses were calculated for each fraction
of HDR brachytherapy. Equivalent dosage in 2 Gy fractions was calculated for
each volume. Total dose to 2cm3 of bowel and bladder were also calculated
using equivalent dose in 2 Gy fractions (α/ß= 3). Average follow-up time and
survival were also calculated.

CONCLUSIONS

Figure 1: Sample CTguided dose distribution
plan with (clockwise from
top left) transverse
image, sagittal
reconstruction, coronal
reconstruction, and 3-D
reconstruction. GTV is
marked in red, CTV in
light green, bowel in
brown, and bladder in
yellow. Isodose lines are
also shown—
Red=160%,
Orange=120%, and
Yellow=100%. The
transparent 100%
isodose cloud
encompassed most of
CTV in 3D display.

Average follow-up was 29 months. Four
patients died from concurrent disease(s) at
an average of 2.83 years after completion of
treatment. Except for one (6.6%) patient
who recurred at 9 months following
completion of treatment, all patients
remained disease-free for the remainder
of follow-up. Side effects were minimal, and
included grade 1-2 diarrhea and dysuria
most commonly.

The Society recommends that the D90 for GTV should be at least 80 Gy, and that the D90
for CTV be at least 48 Gy with intracavitary brachytherapy alone and at least 65 Gy when
combined with EBRT.2 Our data demonstrate that at a dose lower than recommended (many of
our patients were treated prior to these recommendations), treatment still has a high likelihood
of success.

Figure 2: Dose volume histogram for the treatment plan in
figure 1 to demonstrate 99% GTV coverage and 80% CTV
coverage with the prescription dose of 1000 cGy while having
relative low dose to the bladder and bowel (including rectum
and sigmoid as well as small bowel labeled as recto-sigmoid)

RESULTS
Eight patients received external beam
radiation therapy (EBRT) followed by
intracavitary HDR brachytherapy. Seven
patients underwent intracavitary HDR
brachytherapy alone. In all patients, mean
cumulative dose to 90% (D90) of GTV was
96.0 Gy (70.5-177.1) in equivalent dose in 2
Gy fractions (EDQ2, α/ß=10). Mean
cumulative D90 EDQ2 to CTV was 51.6 Gy
(18.6-74).

Comorbid conditions are common in patients with low-grade, endometrioid type
endometrial cancer. Most often, a combination of morbid obesity, diabetes, severe COPD, prior
history of DVT with or without pulmonary embolism, and cardiac disease, which increase
surgical risks, are also likely causes of premature death. In the event of inoperability due to the
severity of these comorbid conditions, an unexpected late recurrence of endometrial cancer
previously treated with radiotherapy is unlikely to be a significant driver of premature mortality
when compared to the patient's other medical problems.

Treatment

Avg D90 EDQ2 GTV Avg D90 EDQ2 CTV D2cc EDQ2 Bowel D2cc EDQ2
Bladder

HDR ICBT

90.8 (73.8-121)

HDR ICBT +
EBRT

100.5 (70.5-177.1) 60.9 (48.1-74)

All patients

96.0

41.0 (18.6-66.6)

42.3 (31.1-52.3) 44.4 (34.7-53.6)

68.0 (60.3-75.0) 63.1 (53.7-70.9)

51.6

Table 1: Average D90 EDQ2 to GTV and CTV, as well as D2cc EDQ2 to bladder and bowel in HDR ICBT alone
and in combination with EBRT. Units: Gy. Ranges shown in parentheses.

Our findings are consistent with other case series in the literature, though those studies
included patients with higher grade disease and histologic subtypes other than endometrioid,
and many used applicators other than tandem and ovoid.3-6 The dosimetry techniques used in
this cohort demonstrate that lower radiotherapy doses to the CTV may provide similar efficacy
to the ABS recommended minimum doses. The use of a single tandem in combination with EBRT
allows greater flexibility in dose distribution without requiring the use of multiple applicators or
dose delivery under general anesthesia. For patients unable to undergo surgical management of
early-stage endometrioid endometrial cancer due to medical contraindications, treatment with
intracavitary HDR brachytherapy is an excellent option for local disease control.
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